We have located links that may give you full text access.
Procedural Sedation for Pediatric Patients with Spinal Muscular Atrophy Undergoing Intrathecal Treatment.
British Journal of Clinical Pharmacology 2023 March 19
AIMS: Nusinersen is administered intrathecally for treating spinal muscular atrophy (SMA). Procedural sedation is common with intrathecal treatment in children. The purpose of this study is to emphasize that intrathecal treatment of pediatric patients with SMA I, II, and III can be tolerated with procedural sedation instead of general anesthesia.
METHODS: Data were collected the from the anesthesia charts and electronic medical records of 14 pediatric patients with SMA types I, II, and III who underwent procedural sedation for repeated intrathecal treatments for SMA. Intravenous induction was performed, and patients were oxygenated with a face mask or nasal cannula while spontaneous breathing continued.
RESULTS: Fourteen patients were included in the study: one SMA I, eight SMA II, and five SMA III. They underwent 88 intrathecal nusinersen injections totally. In the one SMA I patient, of eight months, the procedure was performed under local anesthesia. In all other patients, the treatments were performed under procedural sedation. Different combinations of midazolam, ketamine, propofol, fentanyl, and remifentanil were used. The mean doses of the agents used were 0.03 mg/kg, 0.97 mg/kg, 2.71 mg/kg, 0.84 mcg/kg and 0.5 mcg/kg respectively. There were no intraoperative or postoperative complications.
CONCLUSION: We found the procedural sedation to be sufficient, safe, and effective in SMA II and III pediatric patients who underwent nusinersen treatment intrathecally, provided anesthetic agents are titrated and administered carefully.
METHODS: Data were collected the from the anesthesia charts and electronic medical records of 14 pediatric patients with SMA types I, II, and III who underwent procedural sedation for repeated intrathecal treatments for SMA. Intravenous induction was performed, and patients were oxygenated with a face mask or nasal cannula while spontaneous breathing continued.
RESULTS: Fourteen patients were included in the study: one SMA I, eight SMA II, and five SMA III. They underwent 88 intrathecal nusinersen injections totally. In the one SMA I patient, of eight months, the procedure was performed under local anesthesia. In all other patients, the treatments were performed under procedural sedation. Different combinations of midazolam, ketamine, propofol, fentanyl, and remifentanil were used. The mean doses of the agents used were 0.03 mg/kg, 0.97 mg/kg, 2.71 mg/kg, 0.84 mcg/kg and 0.5 mcg/kg respectively. There were no intraoperative or postoperative complications.
CONCLUSION: We found the procedural sedation to be sufficient, safe, and effective in SMA II and III pediatric patients who underwent nusinersen treatment intrathecally, provided anesthetic agents are titrated and administered carefully.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app